Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Sonnet BioTherapeutics Holdings ( (SONN) ).
On June 30, 2025, Sonnet BioTherapeutics Holdings, Inc. completed a sale of $2.0 million in convertible notes to accredited investors, along with warrants to purchase 865,052 shares of common stock. The convertible notes, maturing on June 30, 2026, can be converted into up to 1,730,104 shares of common stock at a conversion price of $1.156. If a subsequent issuance of at least $5.0 million occurs within 90 days, the notes will automatically convert into the same securities issued in that offering.
The most recent analyst rating on (SONN) stock is a Buy with a $240.00 price target. To see the full list of analyst forecasts on Sonnet BioTherapeutics Holdings stock, see the SONN Stock Forecast page.
Spark’s Take on SONN Stock
According to Spark, TipRanks’ AI Analyst, SONN is a Underperform.
Sonnet BioTherapeutics Holdings is facing severe financial instability, highlighted by consistent losses and negative cash flows. The technical indicators show bearish trends, while valuation metrics reflect unprofitability. The Nasdaq non-compliance notice adds to the risk, potentially leading to delisting, which could further impact investor confidence and capital access.
To see Spark’s full report on SONN stock, click here.
More about Sonnet BioTherapeutics Holdings
Average Trading Volume: 44,896
Technical Sentiment Signal: Sell
Current Market Cap: $3.83M
See more insights into SONN stock on TipRanks’ Stock Analysis page.